Prolonged serum half-life of a recombinant fusion protein linking activated coagulation factor vii with albumin (rVIIa-FP) in different preclinical species

被引：0
|
作者：
Dickneite, G. [1 ]
Zollner, S. [1 ]
Weimer, T. [1 ]
Schmidbauer, S. [1 ]
Raquet, E. [1 ]
Mueller-Cohrs, J. [1 ]
Pragst, I [1 ]
Schulte, S. [1 ]
机构：
[1] CSL Behring GmbH, Preclin R&D, Marburg, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2011年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-TU-246
引用
下载
收藏
页码：385 / 386
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B
    Santagostino, Elena
    Voigt, Christine
    Wolko, Denise
    Cole, Grace
    Li, Yanyan
    Jacobs, Iris C.
    BLOOD, 2015, 126 (23)
  • [42] Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B
    Lubetsky, Aaron
    Lissitchkov, Toshko
    Santagostino, Elena
    Jotov, Gantcho
    Barazani-Brutman, Tami
    Voigt, Christine
    Moises, Tina
    Jacobs, Iris C.
    Martinowitz, Uri
    BLOOD, 2013, 122 (21)
  • [43] Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin ( rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries
    Negrier, Claude
    Lepatan, Lynda Mae
    Karim, Faralzah
    Lienhart, Anne
    Wolko, Denise
    Voigt, Christine
    Jacobs, Iris C.
    Santagostino, Elena
    BLOOD, 2015, 126 (23)
  • [44] Interim results of a phase IIIb safety and efficacy extension study of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B
    Santagostino, Elena
    Voigt, Christine
    Wolko, Denise
    Li, Yanyan
    Strelecki, Mara
    Cole, Grace
    Blackman, Nicole
    Jacobs, Iris
    HAEMOPHILIA, 2016, 22 : 52 - 52
  • [45] Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries
    Negrier, C.
    Lepatan, L. M. P.
    Karim, F. Abdul
    Lienhart, A.
    Lopez Fernandez, M. F.
    Pabinger, I.
    Mahlangu, J.
    Wolko, D.
    Voigt, C.
    Jacobs, I.
    Santagostino, E.
    HAEMOPHILIA, 2016, 22 : 63 - 63
  • [46] First human dose trial of subcutaneously administered recombinant activated factor VII (rFVIIa) to hemophilia A and B patients shows prolonged FVIIa half-life, and provides evidence of safety and tolerability
    Tiede, A.
    Lethagen, S.
    Friedrich, U.
    Stenmo, C.
    Allen, G.
    Giangrande, P.
    Goudemand, J.
    Hay, C.
    Holmstrom, M.
    Klamroth, R.
    Mckenzie, S.
    Miesbach, W.
    Negrier, C.
    Jimenez Yuste, V.
    Berntorp, E.
    HAEMOPHILIA, 2010, 16 : 68 - 68
  • [47] Efficacy and safety results of a phase 3 pivotal clinical study of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated patients with hemophilia B
    Santagostino, E.
    Martinowitz, U.
    Lissitchkov, T.
    Pan-Petesch, B.
    Hanabusa, H.
    Oldenburg, J.
    Boggio, L.
    Negrier, C.
    Pabinger-Fasching, I
    Prondzinski, von Depka M.
    Altisent, C.
    Castaman, G.
    Yamamoto, K.
    Alvarez-Roman, M.
    Voigt, C.
    Jacobs, I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 228 - 228
  • [48] Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (RIX-FP) in Previously Treated Children with Hemophilia B: Efficacy and Safety from a Phase 3 Pivotal Clinical Trial
    Kenet, G.
    Chambost, H.
    Male, C.
    Lambert, T.
    Alvarez-Roman, M-T
    Halimeh, S.
    Chan, A.
    Barnes, C.
    Chernova, T.
    Blatny, J.
    Mancuso, M. E.
    Meunier, S.
    Komrska, V.
    Laws, H-J
    Morfini, M.
    Curtin, J.
    Blazek, B.
    Voigt, C.
    Jacobs, I.
    Santagostino, E.
    HAEMOPHILIA, 2016, 22 : 22 - 23
  • [49] Safety and pharmacokinetic results of a phase I/II clinical trial of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B (PROLONG-9FP)
    Lubetsky, A.
    Lissitchkov, T.
    Yotov, G.
    Luboshitz, J.
    Lelazari, S.
    Barazani-Brutman, T.
    Santagostino, E.
    Voigt, C.
    Zanette, M.
    Jacobs, I.
    Martinowitz, U.
    HAEMOPHILIA, 2012, 18 : 24 - 24
  • [50] Efficacy, PK and safety results of a Phase I/II clinical study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B
    Martinowitz, U.
    Lubetsky, A.
    Santagostino, E.
    Jotov, G.
    Brutman-Barazani, T.
    Voigt, C.
    Moises, T.
    Jacobs, I
    Lissitchkov, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 240 - 241
12345